NPPA issues revised prices for 543 cancer drug brands, effective 9 November 2026
NPPA released a list of revised MRPs for 543 brands of cancer medicines on 28 October 2026, to take effect from 9 November 2026. The change directly affects cancer patients and families who buy these drugs.
What this means for you
If you or someone in your family is being treated for cancer, the prices of these medicines will change from 9 November 2026. For brands on the list, chemists should charge the new MRP. Check the price printed on the pack when you buy, and ask your chemist about the new list if you are charged the old price.
Key facts
- Revised MRPs issued for 543 brands of cancer medicines.
- New prices take effect from 9 November 2026.
- The list includes information submitted by companies up to 27 October 2026.
- On 17 October 2026, NPPA announced trade margin rationalisation for 137 non-scheduled cancer drugs.
- Example: Anarzol (10 tablets) MRP cut from Rs 695.76 to Rs 73.00.
- Example: Bevacizab (4 ml vial) MRP cut from Rs 21,767.70 to Rs 5,930.13.
What has happened
The National Pharmaceutical Pricing Authority (NPPA) has released a list of revised maximum retail prices (MRP) for 543 brands of cancer medicines. The list was issued on 28 October 2026 and the new prices take effect from 9 November 2026. NPPA works under the Ministry of Chemicals and Fertilizers and the Department of Pharmaceuticals.
MRP is the maximum price at which a medicine can be sold at a retail shop.
Why the prices changed
The list includes information submitted by companies up to 27 October 2026. Earlier, on 17 October 2026, NPPA announced trade margin rationalisation (TMR) for 137 non-scheduled cancer drugs in the public interest, to address excessive trade margins, make cancer treatment more affordable and improve access to these medicines. Manufacturers were directed to submit their revised lists to NPPA.
Which medicines cost less
The list includes brands from well-known companies. For example, RGP Life Sciences’ Anarzol (Anastrozole 1 mg, 10 tablets) has an MRP cut from Rs 695.76 to Rs 73.00. Abbott Healthcare’s Bevacizab (Bevacizumab 100 mg/4 ml injection, 4 ml vial) has an MRP cut from Rs 21,767.70 to Rs 5,930.13.
Similarly, Dr Reddy’s Azacitin (Azacitidine 100 mg injection) comes down from Rs 6,337.00 to Rs 1,495.04, Natco’s Dasnat 20 (Dasatinib 20 mg, 60 tablets) from Rs 2,812.50 to Rs 1,085.93, and RGP Life Sciences’ Debrumab 60 mg from Rs 22,031.25 to Rs 5,941.00.
Which patients benefit
According to NPPA, the 137 non-scheduled cancer drugs include immunotherapy medicines used to treat more than 20 types of cancer. These include Denosumab, used by breast and prostate cancer patients; Pegfilgrastim, used to prevent neutropenia in cancer patients; and Bevacizumab, approved for the treatment of colon, ovarian and cervical cancer.
The list will grow
NPPA said the list will be updated as manufacturers submit their revised prices for non-scheduled cancer drugs. The full list of 543 brands is available on the NPPA portal, which is updated regularly.
What patients and families should do
Check the price printed on the pack when buying a medicine. After 9 November 2026, brands on the list should be sold at the new MRP. For the full list and updates, check the NPPA portal.
Questions and answers
When do the new cancer drug prices apply?
From 9 November 2026. NPPA issued the revised MRP list on 28 October 2026, and the prices apply from that date.
How many medicines have new prices?
543 brands of cancer medicines. The full list with revised MRPs is available on the NPPA portal.
Can more medicines be added to the list?
Yes. NPPA said the list will be updated as manufacturers submit revised prices for non-scheduled cancer drugs.
Why were the prices changed?
On 17 October 2026, NPPA announced trade margin rationalisation for 137 non-scheduled cancer drugs to address excessive trade margins and make treatment more affordable.
Where can I see the new prices?
In the list published on the NPPA portal, which NPPA says is updated regularly.
Source: PIB, "एनपीपीए ने कैंसर रोधी 543 ब्रांड की दवाओं के संशोधित एमआरपी जारी किए; सूची को लगातार अपडेट किया जाएगा; नई कीमतें 9 नवंबर, 2026 से प्रभावी होंगी", 28 October 2026. Read the original notice
This routine notice was drafted with AI from an official source and published automatically; an editor reviews it after publishing. Report an error